Dermatan sulfate is a naturally occurring antithrombotic glycosaminoglycan. The antithrombin activity of several dermatan sulfate preparations has been measured in whole human plasma and found to be -55% of that in purified systems. Kinetic studies under pseudo- first-order conditions indicated that the reduction in antithrombin activity of dermatan sulfate in plasma compared with that in buffer was due to noncompetitive inhibition with respect to dermatan sulfate. Analysis of the protein profile bound to immobilized dermatan sulphate showed that on a molar basis, histidine-rich glycoprotein and apolipoprotein E were the most abundant proteins specifically bound, together with significant amounts of fibrinogen and vitronectin. Addition of these proteins to the purified system showed that only fibrinogen inhibited the antithrombin activity of dermatan sulfate and that it did so in a concentration-dependent manner over the physiologic range of plasma fibrinogen levels. These results indicate that the anticoagulant activity of dermatan sulfate may be modulated in human plasma by fibrinogen.
ARTICLES|
February 1, 1995
Fibrinogen inhibits the heparin cofactor II-mediated antithrombin activity of dermatan sulfate
Blood (1995) 85 (3): 720–726.
Citation
A Zammit, J Dawes; Fibrinogen inhibits the heparin cofactor II-mediated antithrombin activity of dermatan sulfate. Blood 1995; 85 (3): 720–726. doi: https://doi.org/10.1182/blood.V85.3.720.bloodjournal853720
Download citation file: